YTHDF1 enhances stemness and chemoresistance in triple-negative breast cancer cells by upregulating SIAH2
- PMID: 37983722
- DOI: 10.1002/mc.23661
YTHDF1 enhances stemness and chemoresistance in triple-negative breast cancer cells by upregulating SIAH2
Abstract
Triple-negative breast cancer (TNBC) is the most lethal and aggressive subtype of breast cancer, and chemoresistance is the major determinant of TNBC treatment failure. This study explores the molecular mechanism of TNBC chemoresistance. The Cancer Genome Atlas, breast cancer integrative platform, and GEPIA databases were used to analyze the expression and correlation of YTHDF1 and seven in absentia homology 2 (SIAH2) in breast cancer. Knockdown of YTHDF1 and SIAH2, or overexpression of SIAH2 in vitro and in vivo, was conducted to evaluate the impact of changes in YTHDF1 and SIAH2 expression on TNBC cell proliferation, apoptosis, stemness, drug resistance, and Hippo pathway gene expression. YTHDF1 and SIAH2 were highly expressed in breast cancer patients and TNBC cells. Knockdown of YTHDF1 and SIAH2 significantly inhibited proliferation and stemness and promoted apoptosis and chemosensitivity of TNBC cells. Mechanistically, the knockdown of YTHDF1 inhibited the expression of SIAH2, thereby downregulating the Hippo pathway, which inhibited proliferation and stemness and promoted apoptosis and chemosensitivity of TNBC cells. The current findings revealed the regulatory mechanism of YTHDF1 in TNBC and clarified the role of the YTHDF1/SIAH2 axis in TNBC drug resistance and stemness. This could provide new insights into the vital role of targeting YTHDF1/SIAH2 to suppress drug resistance and stemness in TNBC cells.
Keywords: Hippo pathway; SIAH2; YTHDF1; drug resistance; stemness; triple-negative breast cancer.
© 2023 The Authors. Molecular Carcinogenesis published by Wiley Periodicals LLC.
Similar articles
-
Long non-coding RNA NEAT1 confers oncogenic role in triple-negative breast cancer through modulating chemoresistance and cancer stemness.Cell Death Dis. 2019 Mar 20;10(4):270. doi: 10.1038/s41419-019-1513-5. Cell Death Dis. 2019. PMID: 30894512 Free PMC article.
-
USP22 Contributes to Chemoresistance, Stemness, and EMT Phenotype of Triple-Negative Breast Cancer Cells by egulating the Warburg Effect via c-Myc Deubiquitination.Clin Breast Cancer. 2023 Feb;23(2):162-175. doi: 10.1016/j.clbc.2022.11.006. Epub 2022 Nov 25. Clin Breast Cancer. 2023. PMID: 36528490
-
The WAVE3/β-catenin oncogenic signaling regulates chemoresistance in triple negative breast cancer.Breast Cancer Res. 2023 Mar 22;25(1):31. doi: 10.1186/s13058-023-01634-3. Breast Cancer Res. 2023. PMID: 36949468 Free PMC article.
-
Unveiling Role of MicroRNAs as Treatment Strategy and Prognostic Markers in Triple Negative Breast Cancer.Curr Pharm Biotechnol. 2020;21(15):1569-1575. doi: 10.2174/1389201021666200627201535. Curr Pharm Biotechnol. 2020. PMID: 32593278 Review.
-
Targeting Triple-Negative Breast Cancer: Resistance Mechanisms and Therapeutic Advancements.Cancer Med. 2025 May;14(9):e70803. doi: 10.1002/cam4.70803. Cancer Med. 2025. PMID: 40318146 Free PMC article. Review.
Cited by
-
Decoding the epitranscriptome: a new frontier for cancer therapy and drug resistance.Cell Commun Signal. 2024 Oct 21;22(1):513. doi: 10.1186/s12964-024-01854-w. Cell Commun Signal. 2024. PMID: 39434167 Free PMC article. Review.
-
Unraveling the role of long non-coding RNAs in therapeutic resistance in acute myeloid leukemia: New prospects & challenges.Noncoding RNA Res. 2024 May 20;9(4):1203-1221. doi: 10.1016/j.ncrna.2024.05.009. eCollection 2024 Dec. Noncoding RNA Res. 2024. PMID: 39036603 Free PMC article. Review.
-
YTHDF1 boosts the lactate accumulation to potentiate cervical cancer cells immune escape.Cell Death Dis. 2024 Nov 18;15(11):843. doi: 10.1038/s41419-024-07128-0. Cell Death Dis. 2024. PMID: 39557826 Free PMC article.
-
SIAH2 is specifically expressed during cervical carcinogenesis, and closely relates to the abnormal proliferation of cervical epithelial cells.Heliyon. 2024 May 17;10(11):e31487. doi: 10.1016/j.heliyon.2024.e31487. eCollection 2024 Jun 15. Heliyon. 2024. PMID: 38828323 Free PMC article.
-
Construction and validation of antibody dependent cell phagocytosis related risk model in breast cancer.Sci Rep. 2025 May 29;15(1):18916. doi: 10.1038/s41598-025-03825-8. Sci Rep. 2025. PMID: 40442365 Free PMC article.
References
REFERENCES
-
- Zhu Y, Liu Z, Gui L, et al. Inhibition of CXorf56 promotes PARP inhibitor-induced cytotoxicity in triple-negative breast cancer. NPJ Breast Cancer. 2023;9(1):34.
-
- Liu R, Shi D, Guo L, et al. Ultrasound-targeted microbubble disruption with key nanodroplets for effective ferroptosis in triple-negative breast cancer using animal model. Int J Nanomedicine. 2023;18:2037-2052.
-
- Bobrie A, Massol O, Ramos J, et al. Association of CD206 protein expression with immune infiltration and prognosis in patients with triple-negative breast cancer. Cancers. 2022;14(19):4829.
-
- Mayer EL, Abramson V, Jankowitz R, et al. TBCRC 030: a phase II study of preoperative cisplatin versus paclitaxel in triple-negative breast cancer: evaluating the homologous recombination deficiency (HRD) biomarker. Ann Oncol. 2020;31(11):1518-1525.
-
- Pantelaiou-Prokaki G, Mieczkowska I, Schmidt GE, et al. HDAC8 suppresses the epithelial phenotype and promotes EMT in chemotherapy-treated basal-like breast cancer. Clin Epigenetics. 2022;14(1):7.
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Molecular Biology Databases